Taltz ® (ixekizumab) injection

80 mg/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Taltz® (Ixekizumab): Dosing for Plaque Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis

PsO: 160 mg at week 0, 80 mg weeks 2,4,6,8,12, then 80 mg every 4 weeks. PsA: 160 mg at week 0, then 80 mg every 4 weeks. AS/r-axSpA: 160 mg at week 0, then 80 mg every 4 weeks. nr-axSpA: 80 mg every 4 weeks.

Ixekizumab Dosage Regimen

Plaque Psoriasis

Ixekizumab is administered by SC injection. The recommended dose is

  • 160 mg (two 80-mg injections) at week 0

  • 80 mg at weeks 2, 4, 6, 8, 10, and 12, then

  • 80 mg Q4W.1

Psoriatic Arthritis

Ixekizumab is administered by SC injection. The recommended dose is

  • 160 mg (two 80-mg injections) at week 0, then

  • 80 mg Q4W.1

For PsA patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for plaque psoriasis.1

Ixekizumab may be administered alone or in combination with a cDMARD (e.g., MTX).1

Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis

Ixekizumab is administered by SC injection. The recommended dose is

  • 160 mg (two 80 mg injections) at week 0, then

  • 80 mg Q4W.1

Non-radiographic Axial Spondyloarthritis

Ixekizumab is administered by SC injection. The recommended dose is 80 mg every 4 weeks.1

Ixekizumab General Administration Guidelines

Tuberculosis Assessment Prior to Initiation of Ixekizumab

Evaluate patients for TB infection prior to initiating treatment with ixekizumab.1

Important Administration Instructions

There are 2 presentations for ixekizumab (ie, autoinjector and prefilled syringe). The ixekizumab “Instructions for Use” for each presentation contains more detailed instructions on the preparation and administration of ixekizumab. 

Ixekizumab is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in SC injection technique using the autoinjector or prefilled syringe.

Each injection is to be administered

  • at a different anatomic location (such as upper arms, thighs or any quadrant of abdomen) than the previous injection, and

  • not into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis.

Administration of ixekizumab in the upper, outer arm may be performed by a caregiver or healthcare provider.

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.1

Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

Reference

1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

Glossary

cDMARD = conventional disease-modifying antirheumatic drug

MTX = methotrexate

NSAID = nonsteroidal anti-inflammatory drug

PsA = psoriatic arthritis

Q4W = every 4 weeks

SC = subcutaneous

TB = tuberculosis

TNF = tumor necrosis factor

Date of Last Review: June 17, 2020


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Chat with us

Submit a Request

Visit Us @LillyMedical